Drug Res (Stuttg) 2021; 71(05): 250-256
DOI: 10.1055/a-1325-0248
Opinion Paper

Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients

1   College of Pharmacy, University of Petra, Amman, Jordan
,
Feras Hawari
2   Section of Pulmonary and Critical Care, Department of Internal Medicine, King Hussein Cancer Center and University of Jordan, Amman, Jordan
3   Cancer Control Office, King Hussein Cancer Center, Amman, Jordan
,
Yasmeen Dodin
3   Cancer Control Office, King Hussein Cancer Center, Amman, Jordan
,
Nour Obeidat
3   Cancer Control Office, King Hussein Cancer Center, Amman, Jordan
› Author Affiliations

Abstract

Despite inconclusive evidence, chloroquine (CQ) and hydroxychloroquine (HCQ)are commonly used for the treatment of Corona virus Disease 2019(COVID-19) in critically ill patients.It was hypothesized that HCQ as an aerosol application can reach the antiviral concentration of ~1–5 μM in the alveolar cells which has been proven effective in vitro. A physiologically-based pharmacokinetic (PBPK) model of nebulized HCQ for pulmonary delivery to COVID-19 patients using the Nasal-Pulmonary Module in GastroPlus® V9.7 simulator, in order to calculate the necessary inhalation dose regimen of HCQ, was developed. The physiological, drug disposition, and pharmacokinetic parameters were obtained from the literature and used during model building after optimization using Optimization Module, while oral data was used for validation. The 25 mg BID inhalation dosing was predicted to lead to alveolar HCQ levels of 7 µM (above EC50 of ~1–5 µM), and small plasma levels of 0.18 µM (as compared to plasma levels of 3.22 µM after 200 mg BID oral dosing). However, average contact time (>1 µM) is around 0.5 h in lung parts, suggesting indirect exposure response effect of HCQ.The developed PBPK model herein predicted HCQ levels in plasma and different lung parts of adults after multiple inhalation dosing regimens for 5 days. This in-silico work needs to be tested in vivo on healthy subjects and COVID-19 patients using 12.5 mg BID and 25 mg BID inhalation doses.



Publication History

Received: 04 September 2020

Accepted: 23 November 2020

Article published online:
30 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Q&A on coronaviruses (COVID-19). Available from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses. Accessed on October 05 2020
  • 2 European Centre for Disease Prevention and Control. COVID-19 situation update worldwide, as of 5 October 2020. Available from https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases. Accessed on October 05 2020
  • 3 Zhou Y, Hou Y, Shen J. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov 2020; 6: 14
  • 4 Salunke S, Alessandrini E, Amin D. et al. Can One Teach Old Drugs New Tricks? Reformulating to Repurpose Chloroquine and Hydroxychloroquine. J Pharmacol Pharm Res 2020; 3: 1-8
  • 5 Rolain M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 2020; 30: 297-308
  • 6 Tripathy S, Dassarma B, Roy S. et al. A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR-CoV-2 (COVID-19) pandemic. Int J Antimicrob Agents 2020; 56: 106028
  • 7 Liu J, Cao R, Xu M. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16
  • 8 Yao X, Ye F, Zhang M. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe Acute Respiratory Distress Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 28.07.2020; 71: 732-739
  • 9 Vincent MJ, Bergeron E, Benjannet S. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005; 2: 69
  • 10 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30: 269-271
  • 11 Kono M, Tatsumi K, Imai AM. et al. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res 2008; 77: 150-152
  • 12 Keyaerts E, Li S, Vijgen L. et al. 2009 Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother 2009; 53: 3416-3421
  • 13 Li X, Wang Y, Agostinis P. et al. Is hydroxychloroquine beneficial for COVID-19 patients?. Cell Death Dis 2020; 11: 512
  • 14 Savarino A, Boelaert JR, Cassone A. et al. Effects of chloroquine on viral infections: an old drug against today's diseases. The Lancet Infectious Diseases 2003; 3: 722-727
  • 15 Fassihi SC, Nabar N, Fassihi R. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19. Br J Pharmacol 2020; 177: 4997-4998
  • 16 Chief Investigators of the RECOVERY Trial. No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Recovery: Randomised Evaluation of COVID-19 Therapy. 2020 Jun. Available from https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19. ccessed on October 05 2020
  • 17 Letter of Revocation, June15, 2020. Available from https://www.fda.gov/media/138945/download. Accessed on October 05 2020
  • 18 COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available from https://www.covid19treatmentguidelines.nih.gov/. Accessed on June 28 2020
  • 19 WHO. Clinical management of COVID-19. [Online] 27 May 2020. Available at https://www.who.int/publications/i/item/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed on June 28 2020
  • 20 Arshad S, Kilgore P, Chaudhry ZS. et al. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. Int J Infect Dis 2020; 97: 396-403
  • 21 Castelnuovo AD, Costanzo S, Antinori A. et al. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: findings from the observational multicentre Italian CORIST study. Eur J Intern Med Published Online First: 25 August 2020
  • 22 Maharaj AR, Wu H, Hornik CP. et al. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019. JAMA Pediatr 2020; 174: e202422
  • 23 Yeo KR, Zhang M, Pan X, Ke AB. et al. 2020 Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling. Clin Pharmacol Ther 2020; 108: 976-984
  • 24 Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. Clin Transl Sci 2020; 13: 642-645
  • 25 Fan J, Zhang X, Liu J. et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients. Clin Infect Dis 2020; DOI: 10.1093/cid/ciaa623. Online ahead of print..
  • 26 Giudicessi JR, Noseworthy PA, Friedman PA. et al. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc 2020; 95: 1213-1221
  • 27 Mahévas M, Viet-thi T, Roumier M. et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial. 2020; DOI: 10.1101/2020.04.10.20060699.
  • 28 Molina JM, Delaugerre C, Legoff J. et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50: 384
  • 29 Vicente J, Zusterzeel R, Johannesen L. et al. Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study. Clin Pharmacol Ther 2019; 105: 943-953
  • 30 Chorin E, Dai M, Shulman E. et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. 2020; DOI: 10.1101/2020.04.02.20047050.
  • 31 Klimke A, Hefner G, Will B. et al. Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. Med Hypotheses 2020; 142: 109783
  • 32 Fassihi SC, Nabar NR, Fassihi R. Novel approach for low-dose pulmonary delivery of hydroxychloroquine in COVID-19. Br J Pharmacol 2020; 177: 4997-4998
  • 33 Kavanagh O, Marie Healy A, Dayton F. et al. Inhaled hydroxychloroquine to improve efficacy and reduce harm in the treatment of COVID-19. Medical Hypotheses 2020; 143: 110110
  • 34 Simulation Plus Inc. Lancaster, CA, USA:
  • 35 Munster T, Gibbs JP, Shen D. et al. Hydroxychloroquine concentration–response relationships in patients with rheumatoid arthritis. Arthritis & Rheumatism 2002; 46: 1460-1469
  • 36 http://www.chemspider.com/; https://pubmed.ncbi.nlm.nih.gov/
  • 37 Kooij S, Astefanei A, Corthals GL. Size distributions of droplets produced by ultrasonic nebulizers. Scientific Reports 2019; 9: 6128 Pasquale Pagliano, Ornella Piazza, Francesco De Caro et al. © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com
  • 38 Pagliano P, Piazza O, De Caro F. et al. Is Hydroxychloroquine a possible post-exposure prophylaxis drug to limit the transmission to health care workers exposed to COVID19?. Clinical Infectious Diseases 2020; 71: 887-888
  • 39 Neu HC, Kumada T, Chin NX. et al. The post-antimicrobial suppressive effect of quinolone agents. Drugs Exp Clin Res 1987; 13: 63-67
  • 40 Kontou P, Chatzika K, Pitsiou G. et al. Pharmacokinetics of Ciprofloxacin and Its Penetration into Bronchial Secretions of Mechanically Ventilated Patients with Chronic Obstructive Pulmonary Disease. Antimicrob Agents Chemother 2011; 55: 4149-4153
  • 41 Arnold SLM, Buckner F. Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. Clin Transl Sci 2020; 13: 642-645